Roberto Pili

  • 10704 Citations
  • 51 h-Index
1990 …2019
If you made any changes in Pure, your changes will be visible here soon.

Publications 1990 2019

2015
58 Citations (Scopus)

Rapid optimization of drug combinations for the optimal angiostatic treatment of cancer

Weiss, A., Ding, X., van Beijnum, J. R., Wong, I., Wong, T. J., Berndsen, R. H., Dormond, O., Dallinga, M., Shen, L., Schlingemann, R. O., Pili, R., Ho, C. M., Dyson, P. J., van den Bergh, H., Griffioen, A. W. & Nowak-Sliwinska, P., Jul 20 2015, In : Angiogenesis. 18, 3, p. 233-244 12 p.

Research output: Contribution to journalArticle

Drug Combinations
Endothelial cells
Endothelial Cells
Pharmaceutical Preparations
Neoplasms
20 Citations (Scopus)

Restriction of dietary protein decreases mTORC1 in tumors and somatic tissues of a tumor-bearing mouse xenograft model

Lamming, D. W., Cummings, N. E., Rastelli, A. L., Gao, F., Cava, E., Bertozzi, B., Spelta, F., Pili, R. & Fontana, L., 2015, In : Oncotarget. 6, 31, p. 31233-31240 8 p.

Research output: Contribution to journalArticle

Dietary Proteins
Heterografts
Fasting
Neoplasms
Proteins
35 Citations (Scopus)

Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications

Adelaiye, R., Ciamporcero, E., Miles, K. M., Sotomayor, P., Bard, J., Tsompana, M., Conroy, D., Shen, L., Ramakrishnan, S., Ku, S. Y., Orillion, A., Prey, J., Fetterly, G., Buck, M., Chintala, S., Bjarnasone, G. A. & Pili, R., Feb 1 2015, In : Molecular Cancer Therapeutics. 14, 2, p. 513-522 10 p.

Research output: Contribution to journalArticle

Renal Cell Carcinoma
Epigenomics
sunitinib
Neoplasms
Histone Code
45 Citations (Scopus)

Tasquinimod modulates suppressive myeloid cells and enhances cancer immunotherapies in murine models

Shen, L., Sundstedt, A., Ciesielski, M., Miles, K. M., Celander, M., Adelaiye, R., Orillion, A., Ciamporcero, E., Ramakrishnan, S., Ellis, L., Fenstermaker, R., Abrams, S. I., Eriksson, H., Leanderson, T., Olsson, A. & Pili, R., Feb 1 2015, In : Cancer immunology research. 3, 2, p. 136-148 13 p.

Research output: Contribution to journalArticle

Myeloid Cells
Immunotherapy
Neoplasms
Immunosuppressive Agents
Prostatic Neoplasms
60 Citations (Scopus)

Testicular cancer, version 2.2015: Clinical pactice guidelines in oncology

Motzer, R. J., Jonasch, E., Agarwal, N., Beard, C., Bhayani, S., Bolger, G. B., Chang, S. S., Choueiri, T. K., Costello, B. A., Derweesh, I. H., Gupta, S., Hancock, S. L., Kim, J. J., Kuzel, T. M., Lam, E. T., Lau, C., Levine, E. G., Lin, D. W., Michaelson, M. D., Olencki, T. & 12 others, Pili, R., Plimack, E. R., Rampersaud, E. N., Redman, B. G., Ryan, C. J., Sheinfeld, J., Shuch, B., Sircar, K., Somer, B., Wilder, R. B., Dwyer, M. & Kumar, R., Jun 1 2015, In : JNCCN Journal of the National Comprehensive Cancer Network. 13, 6, p. 772-799 28 p.

Research output: Contribution to journalReview article

Seminoma
Testicular Neoplasms
Guidelines
Germ Cell and Embryonal Neoplasms
Serum
37 Citations (Scopus)

Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer

Kirk, J. S., Schaarschuch, K., Dalimov, Z., Lasorsa, E., Ku, S. Y., Ramakrishnan, S., Hu, Q., Azabdaftari, G., Wang, J., Pili, R. & Ellis, L., 2015, In : Oncotarget. 6, 5, p. 3136-3146 11 p.

Research output: Contribution to journalArticle

Epigenomics
Prostatic Neoplasms
Etoposide
Therapeutics
Neoplasms
2014
17 Citations (Scopus)

Acquired tumor cell resistance to sunitinib causes resistance in a HT-29 human colon cancer xenograft mouse model without affecting sunitinib biodistribution or the tumor microvasculature

Gotink, K. J., Broxterman, H. J., Honeywell, R. J., Dekker, H., de Haas, R. R., Miles, K. M., Adelaiye, R., Griffioen, A. W., Peters, G. J., Pili, R. & Verheul, H. M. W., 2014, In : Oncoscience. 1, 12, p. 844-853 10 p.

Research output: Contribution to journalArticle

Microvessels
Heterografts
Colonic Neoplasms
Neoplasms
sunitinib
5 Citations (Scopus)

Active ageing and success: A brief history of conceptual models

Petretto, D. R., Pili, R., Gaviano, L., Matos López, C. & Zuddas, C., Nov 28 2014, (Accepted/In press) In : Revista Espanola de Geriatria y Gerontologia.

Research output: Contribution to journalArticle

30 Citations (Scopus)

Active smokingmay negatively affect response rate, progression-free survival, and overall survival of patients with metastatic renal cell carcinoma treatedwith sunitinib

Keizman, D., Gottfried, M., Ish-Shalom, M., Maimon, N., Peer, A., Neumann, A., Hammers, H., Eisenberger, M. A., Sinibaldi, V., Pili, R., Hayat, H., Kovel, S., Sella, A., Boursi, B., Weitzen, R., Mermershtain, W., Rouvinov, K., Berger, R. & Carducci, M. A., 2014, In : Oncologist. 19, 1, p. 51-60 10 p.

Research output: Contribution to journalArticle

Renal Cell Carcinoma
Disease-Free Survival
Smoking
Survival
Hypertension
10 Citations (Scopus)

Alterations in chromatin accessibility and DNA methylation in clear cell renal cell carcinoma

Buck, M. J., Raaijmakers, L. M., Ramakrishnan, S., Wang, D., Valiyaparambil, S., Liu, S., Nowak, N. J. & Pili, R., Oct 9 2014, In : Oncogene. 33, 41, p. 4961-4965 5 p.

Research output: Contribution to journalArticle

DNA Methylation
Renal Cell Carcinoma
Formaldehyde
Chromatin
Neoplasms
4 Citations (Scopus)

An open-label study to determine the maximum tolerated dose of the multitargeted tyrosine kinase inhibitor CEP-11981 in patients with advanced cancer

Pili, R., Carducci, M., Brown, P. & Hurwitz, H., Dec 1 2014, In : Investigational New Drugs. 32, 6, p. 1258-1268 11 p.

Research output: Contribution to journalArticle

Maximum Tolerated Dose
Protein-Tyrosine Kinases
Neoplasms
Neutropenia
Vascular Endothelial Growth Factor A
32 Citations (Scopus)

Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC)1A.J.A. and R.K. contributed equally to this work

Armstrong, A. J., Kaboteh, R., Carducci, M. A., Damber, J. E., Stadler, W. M., Hansen, M., Edenbrandt, L., Forsberg, G., Nordle, Ö., Pili, R. & Morris, M. J., 2014, In : Urologic Oncology: Seminars and Original Investigations. 32, 8, p. 1308-1316 9 p.

Research output: Contribution to journalArticle

Castration
Prostatic Neoplasms
Randomized Controlled Trials
Placebos
Bone and Bones
11 Citations (Scopus)

Combination of HDAC inhibitor MS-275 and IL-2 increased anti-tumor effect in a melanoma model via activated cytotoxic T cells

Kato, Y., Yoshino, I., Egusa, C., Maeda, T., Pili, R. & Tsuboi, R., 2014, In : Journal of Dermatological Science. 75, 2, p. 140-147 8 p.

Research output: Contribution to journalArticle

Histone Deacetylase Inhibitors
T-cells
Interleukin-2
Tumors
Melanoma
22 Citations (Scopus)

Dll4 blockade potentiates the anti-tumor Effects of VEGF inhibition in renal cell carcinoma patient-derived xenografts

Miles, K. M., Seshadri, M., Ciamporcero, E., Adelaiye, R., Gillard, B., Sotomayor, P., Attwood, K., Shen, L., Conroy, D., Kuhnert, F., Lalani, A. S., Thurston, G. & Pili, R., Nov 13 2014, In : PLoS One. 9, 11, e112371.

Research output: Contribution to journalArticle

vascular endothelial growth factors
kidney cells
Renal Cell Carcinoma
Heterografts
Vascular Endothelial Growth Factor A
9 Citations (Scopus)

Generation of a syngeneic orthotopic transplant model of prostate cancer metastasis

Ellis, L., Lehet, K., Ku, S. Y., Azabdaftari, G. & Pili, R., 2014, In : Oncoscience. 1, 10, p. 609-613 5 p.

Research output: Contribution to journalArticle

Prostatic Neoplasms
Neoplasm Metastasis
Transplants
Lymph
Androgens
16 Citations (Scopus)

High-dose interleukin-2 therapy for metastatic renal cell carcinoma: A contemporary experience

Hanzly, M., Aboumohamed, A., Yarlagadda, N., Creighton, T., Digiorgio, L., Fredrick, A., Rao, G., Mehedint, D., George, S., Attwood, K., Kauffman, E., Narashima, D., Khushalani, N. I., Pili, R. & Schwaab, T., 2014, In : Urology. 83, 5, p. 1129-1134 6 p.

Research output: Contribution to journalArticle

Renal Cell Carcinoma
Interleukin-2
Kidney
Therapeutics
Disease-Free Survival
7 Citations (Scopus)

Inhibition of Hsp90 augments docetaxel therapy in castrate resistant prostate cancer

Ku, S. Y., Lasorsa, E., Adelaiye, R., Ramakrishnan, S., Ellis, L. & Pili, R., Jul 29 2014, In : PLoS One. 9, 7, e103680.

Research output: Contribution to journalArticle

docetaxel
HSP90 Heat-Shock Proteins
Androgen Receptors
prostatic neoplasms
Prostatic Neoplasms
43 Citations (Scopus)

Kidney cancer, version 2.2014

Motzer, R. J., Jonasch, E., Agarwal, N., Beard, C., Bhayani, S., Bolger, G. B., Chang, S. S., Choueiri, T. K., Derweesh, I. H., Gupta, S., Hancock, S. L., Kim, J. J., Kuzel, T. M., Lam, E. T., Lau, C., Levine, E. G., Lin, D. W., Margolin, K. A., Michaelson, M. D., Olencki, T. & 12 others, Pili, R., Plimack, E. R., Rampersaud, E. N., Redman, B. G., Ryan, C. J., Sheinfeld, J., Sircar, K., Somer, B., Wang, J., Wilder, R. B., Dwyer, M. A. & Kumar, R., Feb 1 2014, In : JNCCN Journal of the National Comprehensive Cancer Network. 12, 2, p. 175-182 8 p.

Research output: Contribution to journalReview article

Kidney Neoplasms
Practice Guidelines
Guidelines
Carcinoma
Therapeutics
14 Citations (Scopus)

Mechanism of action and clinical activity of tasquinimod in castrate-resistant prostate cancer

Gupta, N., Ustwani, O. A., Shen, L. & Pili, R., Feb 12 2014, In : OncoTargets and Therapy. 7, p. 223-234 12 p.

Research output: Contribution to journalArticle

Prostatic Neoplasms
Pharmaceutical Preparations
Drug Approval
Phase III Clinical Trials
Phase II Clinical Trials
31 Citations (Scopus)

Mechanisms of action of tasquinimod on the tumour microenvironment

Raymond, E., Dalgleish, A., Damber, J. E., Smith, M. & Pili, R., Jan 2014, In : Cancer Chemotherapy and Pharmacology. 73, 1, p. 1-8 8 p.

Research output: Contribution to journalReview article

Tumor Microenvironment
Tumors
Myeloid Cells
Neoplasms
Immunosuppressive Agents
8 Citations (Scopus)

Modeling spontaneous metastatic renal cell carcinoma (mRCC) in mice following nephrectomy

Tracz, A., Mastri, M., Lee, C. R., Pili, R. & Ebos, J. M. L., 2014, In : Journal of visualized experiments : JoVE. 86

Research output: Contribution to journalArticle

Nephrectomy
Renal Cell Carcinoma
Tumors
Cells
Disease Progression
2013
45 Citations (Scopus)

A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer

Pili, R., Qin, R., Flynn, P. J., Picus, J., Millward, M., Ho, W. M., Pitot, H., Tan, W., Miles, K. M., Erlichman, C. & Vaishampayan, U., Dec 2013, In : Clinical Genitourinary Cancer. 11, 4, p. 477-483 7 p.

Research output: Contribution to journalArticle

Vascular Endothelial Growth Factor Receptor
Protein-Tyrosine Kinases
Safety
Neoplasms
Carcinoma
2 Citations (Scopus)

Cancer of the Kidney

Pili, R., Kauffman, E. & Rodriguez, R., Oct 22 2013, Abeloff's Clinical Oncology: Fifth Edition. Elsevier Inc., p. 1416-1444.e5

Research output: Chapter in Book/Report/Conference proceedingChapter

Kidney Neoplasms
44 Citations (Scopus)

Combinatorial antitumor effect of HDACs and the PI3K-Akt-mTOR pathway inhibition in a Pten deficient model of prostate cancer

Ellis, L., Ku, S. Y., Ramakrishnan, S., Lasorsa, E., Azabdaftari, G., Godoy, A. & Pili, R., Dec 2013, In : Oncotarget. 4, 12, p. 2225-2236 12 p.

Research output: Contribution to journalArticle

Histone Deacetylases
Androgen Receptors
Phosphatidylinositol 3-Kinases
Prostatic Neoplasms
DNA Damage
53 Citations (Scopus)

Dietary protein restriction inhibits tumor growth in human xenograft models of prostate and breast cancer

Fontana, L., Adelaiye, R. M., Rastelli, A. L., Miles, K. M., Ciamporcero, E., Longo, V. D., Nguyen, H., Vessella, R. & Pili, R., Dec 2013, In : Oncotarget. 4, 12, p. 2451-2461 11 p.

Research output: Contribution to journalArticle

Dietary Proteins
Heterografts
Prostatic Neoplasms
Breast Neoplasms
Diet
14 Citations (Scopus)

Histone deacetylase inhibitors and epigenetic modifications as a novel strategy in renal cell carcinoma

Ramakrishnan, S. & Pili, R., Jul 2013, In : Cancer Journal (United States). 19, 4, p. 333-340 8 p.

Research output: Contribution to journalReview article

Histone Deacetylase Inhibitors
Renal Cell Carcinoma
Epigenomics
Histones
Chromatin Assembly and Disassembly
11 Citations (Scopus)

Histone modifications: Implications in renal cell carcinoma

Ramakrishnan, S., Ellis, L. & Pili, R., Aug 2013, In : Epigenomics. 5, 4, p. 453-462 10 p.

Research output: Contribution to journalArticle

Histone Code
Renal Cell Carcinoma
Kidney Pelvis
Epigenomics
Genes
33 Citations (Scopus)

Long-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancer

Armstrong, A. J., Häggman, M., Stadler, W. M., Gingrich, J. R., Assikis, V., Polikoff, J., Damber, J. E., Belkoff, L., Nordle, Ö., Forsberg, G., Carducci, M. A. & Pili, R., Dec 15 2013, In : Clinical Cancer Research. 19, 24, p. 6891-6901 11 p.

Research output: Contribution to journalArticle

Castration
Multicenter Studies
Prostatic Neoplasms
Biomarkers
Survival
1 Citation (Scopus)

Major response to cyclophosphamide and prednisone in recurrent castration-resistant prostate cancer

Batty, N., Yarlagadda, N. & Pili, R., Aug 1 2013, In : JNCCN Journal of the National Comprehensive Cancer Network. 11, 8, p. 911-915 5 p.

Research output: Contribution to journalArticle

Castration
Prednisone
Cyclophosphamide
Prostatic Neoplasms
docetaxel
5 Citations (Scopus)

Tasquinimod: A novel angiogenesis inhibitor-development in prostate cancer

George, S. & Pili, R., Apr 2013, In : Current Oncology Reports. 15, 2, p. 65-68 4 p.

Research output: Contribution to journalArticle

Angiogenesis Inhibitors
Prostatic Neoplasms
Castration
Therapeutics
Drug Therapy
26 Citations (Scopus)

Understanding avoidance, refusal, and abandonment of chemotherapy before and after cystectomy for bladder cancer

Rehman, S., Crane, A., Din, R., Raza, S. J., Shi, Y., Wilding, G., Levine, E. G., George, S., Pili, R., Trump, D. L. & Guru, K. A., Dec 2013, In : Urology. 82, 6, p. 1370-1375 6 p.

Research output: Contribution to journalArticle

Cystectomy
Urinary Bladder Neoplasms
Drug Therapy
Referral and Consultation
Medical Oncology
13 Citations (Scopus)

Use of a Glycolipid Inhibitor to Ameliorate Renal Cancer in a Mouse Model

Chatterjee, S., Alsaeedi, N., Hou, J., Bandaru, V. V. R., Wu, L., Halushka, M. K., Pili, R., Ndikuyeze, G. & Haughey, N. J., May 9 2013, In : PLoS One. 8, 5, e63726.

Research output: Contribution to journalArticle

kidney neoplasms
Glycosphingolipids
Kidney Neoplasms
glycolipids
Glycolipids
2012
26 Citations (Scopus)

A phase I/IIA study of AGS-PSCA for castration-resistant prostate cancer

Morris, M. J., Eisenberger, M. A., Pili, R., Denmeade, S. R., Rathkopf, D., Slovin, S. F., Farrelly, J., Chudow, J. J., Vincent, M., Scher, H. I. & Carducci, M. A., Oct 2012, In : Annals of Oncology. 23, 10, p. 2714-2719 6 p., mds078.

Research output: Contribution to journalArticle

Castration
Prostate
Prostatic Neoplasms
Stem Cells
Antigens
46 Citations (Scopus)

A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malate

Bruce, J. Y., Eickhoff, J., Pili, R., Logan, T., Carducci, M., Arnott, J., Treston, A., Wilding, G. & Liu, G., Apr 2012, In : Investigational New Drugs. 30, 2, p. 794-802 9 p.

Research output: Contribution to journalArticle

Renal Cell Carcinoma
Nanoparticles
Disease Progression
2-methoxyestradiol
sunitinib
42 Citations (Scopus)

Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma

Keizman, D., Ish-Shalom, M., Pili, R., Hammers, H., Eisenberger, M. A., Sinibaldi, V., Boursi, B., Maimon, N., Gottfried, M., Hayat, H., Peer, A., Kovel, S., Sella, A., Berger, R. & Carducci, M. A., May 2012, In : European Journal of Cancer. 48, 7, p. 1031-1037 7 p.

Research output: Contribution to journalArticle

Diphosphonates
Renal Cell Carcinoma
Disease-Free Survival
Neoplasm Metastasis
Bone and Bones
19 Citations (Scopus)

Class I histone deacetylase inhibition is a novel mechanism to target regulatory T cells in immunotherapy

Shen, L. & Pili, R., 2012, In : OncoImmunology. 1, 6, p. 948-950 3 p.

Research output: Contribution to journalArticle

Histone Deacetylase Inhibitors
Histone Deacetylases
Regulatory T-Lymphocytes
Immunotherapy
Immune Tolerance
82 Citations (Scopus)

Class I Histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models

Shen, L., Ciesielski, M., Ramakrishnan, S., Miles, K. M., Ellis, L., Sotomayor, P., Shrikant, P., Fenstermaker, R. & Pili, R., Jan 27 2012, In : PLoS One. 7, 1, e30815.

Research output: Contribution to journalArticle

kidney neoplasms
histone deacetylase
Histone Deacetylase Inhibitors
T-cells
Kidney Neoplasms
39 Citations (Scopus)

Contrasting effects of sunitinib within in vivo models of metastasis

Welti, J. C., Powles, T., Foo, S., Gourlaouen, M., Preece, N., Foster, J., Frentzas, S., Bird, D., Sharpe, K., Weverwijk, A. V., Robertson, D., Soffe, J., Erler, J. T., Pili, R., Springer, C. J., Mather, S. J. & Reynolds, A. R., 2012, In : Angiogenesis. 15, 4, p. 623-641 19 p.

Research output: Contribution to journalArticle

Tumors
Neoplasm Metastasis
Neoplasms
Lung
Cells
9 Citations (Scopus)

Development of a castrate resistant transplant tumor model of prostate cancer

Ellis, L., Lehet, K., Ramakrishnan, S., Adelaiye, R. & Pili, R., May 1 2012, In : Prostate. 72, 6, p. 587-591 5 p.

Research output: Contribution to journalArticle

Prostatic Neoplasms
Transplants
Neoplasms
Androgens
Androgen Receptors
20 Citations (Scopus)

Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer

Tolcher, A. W., Chi, K. N., Shore, N. D., Pili, R., Molina, A., Acharya, M., Kheoh, T., Jiao, J. J., Gonzalez, M., Trinh, A., Pankras, C. & Tran, N., Aug 2012, In : Cancer Chemotherapy and Pharmacology. 70, 2, p. 305-313 9 p.

Research output: Contribution to journalArticle

Castration
Prednisone
Prostatic Neoplasms
Electrocardiography
Pharmacokinetics

Epigenetic targeting and histone deacetylase inhibition in RCC

Ramakrishnan, S. & Pili, R., Nov 1 2012, Renal Cell Carcinoma: Translational Biology, Personalized Medicine, and Novel Therapeutic Targets. Springer US, Vol. 9781461424000. p. 193-211 19 p.

Research output: Chapter in Book/Report/Conference proceedingChapter

Histone Deacetylases
Renal Cell Carcinoma
Epigenomics
Histone Code
Neoplasms
11 Citations (Scopus)

Mind the gap: Potential for rebounds during antiangiogenic treatment breaks

Ebos, J. M. L. & Pili, R., Jul 15 2012, In : Clinical Cancer Research. 18, 14, p. 3719-3721 3 p.

Research output: Contribution to journalArticle

Vascular Endothelial Growth Factor A
Blood Vessels
Neoplasms
Appointments and Schedules
Endothelial Cells
15 Citations (Scopus)

Modulation of chemotherapeutic efficacy by vascular disrupting agents: Optimizing the sequence and schedule

Wang, E. S., Pili, R. & Seshadri, M., Mar 1 2012, In : Journal of Clinical Oncology. 30, 7, p. 760-761 2 p.

Research output: Contribution to journalLetter

Antineoplastic Combined Chemotherapy Protocols
Xanthones
Molecular Targeted Therapy
Statistical Data Interpretation
Angiogenesis Inhibitors
33 Citations (Scopus)

Nanosponge-encapsulated camptothecin exerts anti-tumor activity in human prostate cancer cells

Minelli, R., Cavalli, R., Ellis, L., Pettazzoni, P., Trotta, F., Ciamporcero, E., Barrera, G., Fantozzi, R., Dianzani, C. & Pili, R., Nov 20 2012, In : European Journal of Pharmaceutical Sciences. 47, 4, p. 686-694 9 p.

Research output: Contribution to journalArticle

Camptothecin
Human Activities
Prostatic Neoplasms
Cyclodextrins
Neoplasms
94 Citations (Scopus)

Phase i study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours

Pili, R., Salumbides, B., Zhao, M., Altiok, S., Qian, D., Zwiebel, J., Carducci, M. A. & Rudek, M. A., Jan 3 2012, In : British Journal of Cancer. 106, 1, p. 77-84 8 p.

Research output: Contribution to journalArticle

NSC 153174
Isotretinoin
Histone Deacetylase Inhibitors
Tretinoin
Neoplasms
62 Citations (Scopus)

Pretreatment neutrophil-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with ketoconazole: Association with outcome and predictive nomogram

Keizman, D., Gottfried, M., Ish-Shalom, M., Maimon, N., Peer, A., Neumann, A., Rosenbaum, E., Kovel, S., Pili, R., Sinibaldi, V., Carducci, M. A., Hammers, H., Eisenberger, M. A. & Sella, A., 2012, In : Oncologist. 17, 12, p. 1508-1514 7 p.

Research output: Contribution to journalArticle

Nomograms
Ketoconazole
Castration
Prostatic Neoplasms
Neutrophils
36 Citations (Scopus)

Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition

Chintala, S., Najrana, T., Toth, K., Cao, S., Durrani, F. A., Pili, R. & Rustum, Y. M., Jul 17 2012, In : BMC Cancer. 12, 293.

Research output: Contribution to journalArticle

Prolyl Hydroxylases
Hypoxia-Inducible Factor 1
Selenium
Renal Cell Carcinoma
Growth
47 Citations (Scopus)

Testicular cancer

Motzer, R. J., Agarwal, N., Beard, C., Bhayani, S., Bolger, G. B., Buyyounouski, M. K., Carducci, M. A., Chang, S. S., Choueiri, T. K., Gupta, S., Hancock, S. L., Hudes, G. R., Jonasch, E., Kuzel, T. M., Lau, C., Levine, E. G., Lin, D. W., Margolin, K. A., Michaelson, M. D., Olencki, T. & 8 others, Pili, R., Ratliff, T. W., Redman, B. G., Robertson, C. N., Ryan, C. J., Sheinfeld, J., Wang, J. & Wilder, R. B., Apr 1 2012, In : JNCCN Journal of the National Comprehensive Cancer Network. 10, 4, p. 502-535 34 p.

Research output: Contribution to journalReview article

132 Citations (Scopus)

The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma

Keizman, D., Ish-Shalom, M., Huang, P., Eisenberger, M. A., Pili, R., Hammers, H. & Carducci, M. A., Jan 2012, In : European Journal of Cancer. 48, 2, p. 202-208 7 p.

Research output: Contribution to journalArticle

Renal Cell Carcinoma
Disease-Free Survival
Neutrophils
Lymphocytes
Survival
13 Citations (Scopus)

Vascular disruption in combination with mTOR inhibition in renal cell carcinoma

Ellis, L., Shah, P., Hammers, H., Lehet, K., Sotomayor, P., Azabdaftari, G., Seshadri, M. & Pili, R., Feb 2012, In : Molecular Cancer Therapeutics. 11, 2, p. 383-392 10 p.

Research output: Contribution to journalArticle

vadimezan
Renal Cell Carcinoma
Blood Vessels
Neoplasms
Heterografts